2026 Q2 - tulosraportti
31 päivää sitten
‧40 min
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 21 | - | - | ||
| 165 | - | - | ||
| 42 | - | - | ||
| 94 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenI've just had the opportunity to read the Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last couple of weeks (the drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both parts could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the share price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy towards 2030 as well as new data.
- ·2 päivää sittenIs it the Morgan Stanley effect, or was it just oversold🧐All sectors are having a good day. Now I've just had the opportunity to read Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last few weeks (a drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the stock price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy until mid-2030 as well as new data.
·3 päivää sittenReally hope the bottom was reached at 290, was so lucky to buy at 376 so it has done well over the last 1.5 weeks
·16.9. · MuokattuWhile the stock price continues to plummet towards 0 or whatever, one can perhaps take a little comfort in the fact that Boehringer Ingelheim has already finished recruiting for the phase 2 study with BI3034701 - 342 patients have been enrolled, more than the originally planned 300. This also means that the planned end date in August 2027 will likely hold. So, if all goes well, phase 3 will probably start relatively early in 2028. They have also initiated some additional smaller phase 1 studies, likely to gain a bit more clarity on optimal dosing and similar.The presentation by MR yesterday to MS was actually good. Not much new, but he emphasized they have a solid base in my view, good capital, a sound pipeline. It was, however, not surprisingly, set up for the R&D day regarding news flow. I think their 2030 roadmap will be the next groundbreaking step. Gubra was also spoken highly of by partners, which is positive. Of 'negative' elements, however, it sounded a bit like not much new will come before the R&D day, so we'll see what tomorrow brings.
·15.9.Can someone explain to me. Has Gubra really become over 40% less valuable this year, and why? Thanks in advance.Absolutely insane that Gubra has fallen 25% in a couple of weeks. It may well be that the interest rate is going up by 0.25%, but the company now has a market cap of around 5 billion, and they have 3 potential Blockbusters in the pipeline (all based on known well-documented analogues, Amylin, Cagrilintid etc.) which can probably each bring in 15 billion in roylties, milestones etc. Gubra's valuation today is, as I see it, akt far too low. Other reasons such as low liquidity etc. are well described elsewhere in this thread, but the price of 5 billion is small change for the big players in this sector. Must now be an obvious acquisition candidate🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
31 päivää sitten
‧40 min
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenI've just had the opportunity to read the Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last couple of weeks (the drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both parts could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the share price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy towards 2030 as well as new data.
- ·2 päivää sittenIs it the Morgan Stanley effect, or was it just oversold🧐All sectors are having a good day. Now I've just had the opportunity to read Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last few weeks (a drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the stock price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy until mid-2030 as well as new data.
- ·3 päivää sittenReally hope the bottom was reached at 290, was so lucky to buy at 376 so it has done well over the last 1.5 weeks
- ·16.9. · MuokattuWhile the stock price continues to plummet towards 0 or whatever, one can perhaps take a little comfort in the fact that Boehringer Ingelheim has already finished recruiting for the phase 2 study with BI3034701 - 342 patients have been enrolled, more than the originally planned 300. This also means that the planned end date in August 2027 will likely hold. So, if all goes well, phase 3 will probably start relatively early in 2028. They have also initiated some additional smaller phase 1 studies, likely to gain a bit more clarity on optimal dosing and similar.The presentation by MR yesterday to MS was actually good. Not much new, but he emphasized they have a solid base in my view, good capital, a sound pipeline. It was, however, not surprisingly, set up for the R&D day regarding news flow. I think their 2030 roadmap will be the next groundbreaking step. Gubra was also spoken highly of by partners, which is positive. Of 'negative' elements, however, it sounded a bit like not much new will come before the R&D day, so we'll see what tomorrow brings.
- ·15.9.Can someone explain to me. Has Gubra really become over 40% less valuable this year, and why? Thanks in advance.Absolutely insane that Gubra has fallen 25% in a couple of weeks. It may well be that the interest rate is going up by 0.25%, but the company now has a market cap of around 5 billion, and they have 3 potential Blockbusters in the pipeline (all based on known well-documented analogues, Amylin, Cagrilintid etc.) which can probably each bring in 15 billion in roylties, milestones etc. Gubra's valuation today is, as I see it, akt far too low. Other reasons such as low liquidity etc. are well described elsewhere in this thread, but the price of 5 billion is small change for the big players in this sector. Must now be an obvious acquisition candidate🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 21 | - | - | ||
| 165 | - | - | ||
| 42 | - | - | ||
| 94 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
31 päivää sitten
‧40 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenI've just had the opportunity to read the Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last couple of weeks (the drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both parts could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the share price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy towards 2030 as well as new data.
- ·2 päivää sittenIs it the Morgan Stanley effect, or was it just oversold🧐All sectors are having a good day. Now I've just had the opportunity to read Morgan Stanley Q&A highlights and overall the Gubra case still looks very exciting, but what has made some investors nervous in the last few weeks (a drop of approx. 25% from price 400 to 300) is partly their changed focus on 1) keeping product development longer in-house before partnership, and 2) the new 3rd business leg Gubra Ventures which will be responsible for potential acquisitions of new products for development. Both could lead to an IPO if current cash holdings and future cash flow are not sufficient to cover this strategy, which means increased risk (of dilution). My guess is that this is the reason for the stock price drop in recent weeks (and perhaps the entire year). The next important date will be October 27th when Gubra holds R&D in London where they will present their strategy until mid-2030 as well as new data.
- ·3 päivää sittenReally hope the bottom was reached at 290, was so lucky to buy at 376 so it has done well over the last 1.5 weeks
- ·16.9. · MuokattuWhile the stock price continues to plummet towards 0 or whatever, one can perhaps take a little comfort in the fact that Boehringer Ingelheim has already finished recruiting for the phase 2 study with BI3034701 - 342 patients have been enrolled, more than the originally planned 300. This also means that the planned end date in August 2027 will likely hold. So, if all goes well, phase 3 will probably start relatively early in 2028. They have also initiated some additional smaller phase 1 studies, likely to gain a bit more clarity on optimal dosing and similar.The presentation by MR yesterday to MS was actually good. Not much new, but he emphasized they have a solid base in my view, good capital, a sound pipeline. It was, however, not surprisingly, set up for the R&D day regarding news flow. I think their 2030 roadmap will be the next groundbreaking step. Gubra was also spoken highly of by partners, which is positive. Of 'negative' elements, however, it sounded a bit like not much new will come before the R&D day, so we'll see what tomorrow brings.
- ·15.9.Can someone explain to me. Has Gubra really become over 40% less valuable this year, and why? Thanks in advance.Absolutely insane that Gubra has fallen 25% in a couple of weeks. It may well be that the interest rate is going up by 0.25%, but the company now has a market cap of around 5 billion, and they have 3 potential Blockbusters in the pipeline (all based on known well-documented analogues, Amylin, Cagrilintid etc.) which can probably each bring in 15 billion in roylties, milestones etc. Gubra's valuation today is, as I see it, akt far too low. Other reasons such as low liquidity etc. are well described elsewhere in this thread, but the price of 5 billion is small change for the big players in this sector. Must now be an obvious acquisition candidate🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 21 | - | - | ||
| 165 | - | - | ||
| 42 | - | - | ||
| 94 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt